Keymeulen, B <br/><br/>
Four-year metabolic outcome of a randomised controlled  CD3-antibody trial in recent-onset type 1 diabetic patients  depends on their age and baseline residual beta cell mass.  [electronic resource] 

 -  Diabetologia  Apr 2010 
 - 614-23 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>1432-0428 
<br/><br/><label>Standard No.: </label>10.1007/s00125-009-1644-9  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Age Factors<br/>Antibodies--therapeutic use<br/>Belgium<br/>CD3 Complex--immunology<br/>Diabetes Mellitus, Type 1--drug therapy<br/>Female<br/>Follow-Up Studies<br/>Glycated Hemoglobin--metabolism<br/>Humans<br/>Insulin-Secreting Cells--physiology<br/>Lymphocyte Subsets--immunology<br/>Male<br/>Placebos<br/>Registries<br/>Time Factors<br/>Young Adult